We report no effect of EBI2, CH25H, or CYP7B1 knockouts in the complex mechanisms of steatosis and inflammation during NASH pathogenesis, making essential effects of EBI2 or its ligand 7α,25-diHC in NAFLD/NASH highly unlikely. The gene discussed is CH25H; the disease is metabolic dysfunction-associated steatotic liver disease.